Nitric oxide inhalation decreases pulmonary artery remodeling in the injured lungs of rat pups

Circulation Research

Volumn 87, Issue 2, 2000, Pages 140-145

  Roberts Jr , Jesse D ^a   Chiche, Jean Daniel ^a   Weimann, Joerg ^a   Steudel, Wolfgang ^a   Zapol, Warren M ^a   Bloch, Kenneth D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bronchopulmonary dysplasia; Congenital heart disease; Inhaled nitric oxide; Proliferation; Pulmonary hypertension

Indexed keywords

NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL TONE; CELL PROLIFERATION; CONGENITAL HEART DISEASE; DRUG EFFECT; LUNG INJURY; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY DISEASE; PULMONARY HYPERTENSION; RAT;

EID: 0034698071     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.87.2.140     Document Type: Article

References (49)

1. Lung biopsy in congenital heart disease: A morphometric approach to pulmonary vascular disease
2. Ultrastructural findings in lung biopsy material from children with congenital heart defects
3. Pulmonary vascular damage and the development of cor pulmonale following hyaline membrane disease
4. Pulmonary hypertension produced in rats by ingestion of Crotalaria spectabilis seeds
5. Arterial changes in Crotalaria spectabilis-induced pulmonary hypertension in rats
6. Interleukin 1 bioactivity in the lungs of rats with monocrotaline-induced pulmonary hypertension
7. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension
8. 3H-thymidine by the cells of the pulmonary circulation and alveolar walls
9. Hypertrophy and prolonged DNA synthesis in smooth muscle cells characterize pulmonary arterial wall thickening after monocrotaline pyrrole administration to rats
10. Development of Crotalaria pulmonary hypertension: Hemodynamic and structural study
11. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension
12. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
13. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active intermediates
14. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
15. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet-derived growth factor
16. Role of endothelium in the maintenance of low pulmonary vascular tone in normal children
17. Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb
18. Inhaled nitric oxide: A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction
19. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat
20. Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats
21. Chronic inhaled nitric oxide: Effects on pulmonary vascular endothelial function and pathology in rats
22. Studies with anti-bromodeoxyuridine antibodies, II: Simultaneous immunocytochemical detection of antigen expression and DNA synthesis by in vivo labeling of mouse intestinal mucosa
23. Nitric oxide inhalation inhibits platelet aggregation and platelet-mediated pulmonary thrombosis in rats
24. Pulmonary toxicity of monocrotaline differs at critical periods of lung development
25. Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension
26. Monocrotaline pyrrole-induced pulmonary hypertension in Fawn-booded rats with platelet storage pool deficiency: 5-hydroxytryptamine uptake by isolated, perfused lungs
27. A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension
28. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats
29. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats
30. Continuous low-dose NO inhalation does not prevent monocrotaline-induced pulmonary hypertension in rats
31. Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats
32. Pulmonary soluble guanylate cyclase, a nitric oxide receptor, is increased during the perinatal period
33. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation
34. Regulation of gene expression by cGMP-dependent protein kinase
35. Cyclic-GMP-dependent protein kinase inhibits the Ras/mitogen-activated protein kinase pathway
36. Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells
37. Nitric oxide reduces vascular smooth muscle cell elastase activity through cGMP-mediated suppression of ERK phosphorylation and AML1B nuclear partitioning
38. Nitric oxide-induced downregulation of Cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells
39. Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists
40. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension
41. Nitric oxide: An endogenous modulator of leukocyte adhesion
42. Nitric oxide prevents leukocyte adherence: Role of superoxide
43. Nitric oxide synthesis inhibition induces leukocyte adhesion via superoxide and mast cells
44. Effects of sodium nitroprasside and other pentacyanonitrosyl complexes on platelet aggregation
45. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium
46. Cardiac surgery in infants with very low birth weight
47. Inhaled nitric oxide in congenital heart disease
48. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn
49. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure